health India's Generic Semaglutide Surge Could Reshape Global Obesity Treatment
With Novo Nordisk's semaglutide patent expiring in India, domestic manufacturers are preparing dozens of affordable generics, potentially slashing costs and expanding access to GLP-1 weight-loss drugs worldwide.
